ID

22148

Descripción

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00312377

Link

https://clinicaltrials.gov/show/NCT00312377

Palabras clave

  1. 21/5/17 21/5/17 -
Subido en

21 de mayo de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Non-small Cell Lung Cancer NCT00312377

Eligibility Non-small Cell Lung Cancer NCT00312377

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
lung cancer patients who answer true to the following statements are eligible to join this clinical study.
Descripción

lung cancer

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0242379
i have a confirmed diagnosis of locally advanced or metastatic non small cell lung cancer (stage iiib - iv)
Descripción

locally advanced or metastatic nsclc

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0679246
UMLS CUI [1,3]
C0027627
i have had 1st line anti-cancer therapy. previous treatment with avastin (bevacizumab) in first line nsclc is allowed.
Descripción

nsclc first line therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C1708063
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
lung cancer patients who answer true to the following are not eligible to join this clinical study.
Descripción

lung cancer

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0242379
i do not have non small cell lung cancer (nsclc)
Descripción

nsclc

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007131
i have received treatment with docetaxel (taxotere). prior treatment with paclitaxel is acceptable.
Descripción

docetaxel

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0246415
i have received 2nd line anti-cancer therapy (for example, patients with previous 2nd line non small cell lung cancer (nsclc) treatment with tarceva (erlotinib, osi-744), alimta (pemetrexed) are not eligible)
Descripción

nsclc second line therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C1710038
i have been treated with vegfr-tyrosine kinase inhibitors (tkis) (sunitinib, sorafenib, other vegf tkis). previous treatment with avastin (bevacizumab) in 1st line non small cell lung cancer is permitted.
Descripción

vegfr tyrosine kinase inhibitors

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2985521
i have a history of uncontrolled irregular heartbeat
Descripción

arrhythmias

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0003811
i have a history of high blood pressure which has not been controlled with medication if you are unsure of the meaning of the inclusion and exclusion criteria above, please contact the call center number for help.
Descripción

hypertension

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0020538

Similar models

Eligibility Non-small Cell Lung Cancer NCT00312377

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
lung cancer
Item
lung cancer patients who answer true to the following statements are eligible to join this clinical study.
boolean
C0242379 (UMLS CUI [1])
locally advanced or metastatic nsclc
Item
i have a confirmed diagnosis of locally advanced or metastatic non small cell lung cancer (stage iiib - iv)
boolean
C0007131 (UMLS CUI [1,1])
C0679246 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
nsclc first line therapy
Item
i have had 1st line anti-cancer therapy. previous treatment with avastin (bevacizumab) in first line nsclc is allowed.
boolean
C0007131 (UMLS CUI [1,1])
C1708063 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
lung cancer
Item
lung cancer patients who answer true to the following are not eligible to join this clinical study.
boolean
C0242379 (UMLS CUI [1])
nsclc
Item
i do not have non small cell lung cancer (nsclc)
boolean
C0007131 (UMLS CUI [1])
docetaxel
Item
i have received treatment with docetaxel (taxotere). prior treatment with paclitaxel is acceptable.
boolean
C0246415 (UMLS CUI [1])
nsclc second line therapy
Item
i have received 2nd line anti-cancer therapy (for example, patients with previous 2nd line non small cell lung cancer (nsclc) treatment with tarceva (erlotinib, osi-744), alimta (pemetrexed) are not eligible)
boolean
C0007131 (UMLS CUI [1,1])
C1710038 (UMLS CUI [1,2])
vegfr tyrosine kinase inhibitors
Item
i have been treated with vegfr-tyrosine kinase inhibitors (tkis) (sunitinib, sorafenib, other vegf tkis). previous treatment with avastin (bevacizumab) in 1st line non small cell lung cancer is permitted.
boolean
C2985521 (UMLS CUI [1])
arrhythmias
Item
i have a history of uncontrolled irregular heartbeat
boolean
C0003811 (UMLS CUI [1])
hypertension
Item
i have a history of high blood pressure which has not been controlled with medication if you are unsure of the meaning of the inclusion and exclusion criteria above, please contact the call center number for help.
boolean
C0020538 (UMLS CUI [1])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial